Clinical trial · Interventional
Identification of Liver Tumours Using BIP - Biopsy System
INJ-LIVERB-01 Identification of Liver Tumours Using BIP - Biopsy System
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical device investigation is conducted by performing liver biopsies using the BIP - Biopsy Tool. The aim is to assess the feasibility of bioimpedance spectroscopy based biopsy tool guidance method and test how well BIP biopsy system is able to distinguish liver tumours from surrounding tissue. In addition, user feedback is obtained to improve the usability of the investigational device. The study does not affect the traditional treatment procedure and only the patients in clinical need for diagnosis by liver biopsy are included on voluntary basis. The invasive products used in actual biopsy operation are designed so that their performance is essentially equal to the currently used biopsy devices, the only difference is the measurement capability of biopsy needle and connection to measurement device.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Biopsy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BIP Biopsy System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BIP Biopsy System
- description
- Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
- interventionNames
- Device: BIP Biopsy System
Primary outcomes (1)
- measure
- Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue
- timeFrame
- During liver biopsy (couple of minutes/patient)
- description
- Liver biopsy is performed in traditional way but with biopsy needle that enables bioimpedance measurement from multiple frequencies (spectrum). Tumorous and nontumorous tissue is measured during ultrasound guided biopsy procedure and the tumorous tissue type is verified by histological biopsy sample analysis. The bioimpedance spectra (impedance and phase angle) are compared with each other and differences in means of the spectra calculated. The data analysis is performed offline.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Consenting adults undergoing ultrasound-guided core liver biopsy to diagnose liver tumour or other abnormalities * Identifiable non-tumorous liver tissue along the planned needle injection path. Exclusion Criteria: * Inability to give informed consent * Being under aged * Being pregnant * Being high risk patient * Lack of identifiable non-tumorous liver tissue along the injection path to the tumour location * Known contraindications to liver biopsy.
References
Publications (0)
Data not yet available